AbbVie Inc.

NYSE:ABBV 株式レポート

時価総額：US$461.3b

AbbVie 将来の成長

Future 基準チェック /46

AbbVie利益と収益がそれぞれ年間26.7%と6.3%増加すると予測されています。EPS は年間 増加すると予想されています。自己資本利益率は 3 年後に228.1% 27.4%なると予測されています。

主要情報

26.7%

収益成長率

27.43%

EPS成長率

Biotechs 収益成長25.1%
収益成長率6.3%
将来の株主資本利益率228.15%
アナリストカバレッジ

Good

最終更新日29 Jun 2026

今後の成長に関する最新情報

Recent updates

ナラティブの更新 • Jun 23

ABBV: Future Returns Will Hinge On Apogee Deal And Immunology Pipeline

Analysts have made only a modest adjustment to AbbVie’s fair value narrative, reflecting a slightly higher discount rate and updated views on margins and long term P/E in light of the proposed $10.9 billion Apogee Therapeutics deal and its implications for competition and atopic dermatitis market potential. Analyst Commentary Recent research on AbbVie around the proposed US$10.9b Apogee Therapeutics acquisition highlights a mix of optimism about growth opportunities in immunology and atopic dermatitis, alongside caution about execution risk, competition, and valuation.
Seeking Alpha • Jun 19

AbbVie: Immunology Cash Flow Funds Oncology Expansion

Summary I continue to cover AbbVie with a 'Buy' rating due to its R&D achievements. So, in the past 3 months, Decnupaz and Skinvive by Juvederm have received FDA approvals. Moreover, a week ago, AbbVie reported promising results from the Phase 3 CLL14 trial for the treatment of chronic lymphocytic leukemia patients. Meanwhile, Venclexta generated $770 million in revenue for AbbVie in Q1, up 15.8% year-over-year and 8.5% QoQ. Also, inthis article, you will know why the superiority of UCB's Bimzelx over Skyriziin the Phase 3 BE BOLD study doesn't threaten the sales growth of AbbVie's IL-23 inhibitor. Read the full article on Seeking Alpha
分析記事 • Jun 16

AbbVie (ABBV) Stock Could Be 12.6% Undervalued After CLL14 Trial Update

AbbVie (ABBV) is back in focus after releasing nine year final results from its Phase 3 CLL14 trial, where a fixed duration venetoclax plus obinutuzumab regimen improved progression free survival in untreated CLL patients. See our latest analysis for AbbVie. The latest CLL14 update lands after a mixed few sessions for AbbVie, with the share price slipping 2.7% on the day to $221.59, while still showing a 5.3% 30 day share price return and a 19.9% one year total shareholder return that points...
ナラティブの更新 • Jun 06

ABBV: Future Returns Will Depend On Expanding Immunology And IBD Pipeline Execution

AbbVie’s updated analyst price target edges higher to $253.55 from $249.43 as analysts factor in slightly higher profit margin assumptions, modestly lower revenue growth expectations, a reduced discount rate, and a somewhat lower future P/E multiple, with recent research highlighting the depth of the inflammatory bowel disease pipeline and broader R&D optionality. Analyst Commentary Recent Street research on AbbVie shows a mix of optimism and caution, with multiple price target revisions clustered within a relatively tight range and commentary that keeps attention on the inflammatory bowel disease pipeline and broader R&D portfolio.
分析記事 • May 15

We Think You Can Look Beyond AbbVie's (NYSE:ABBV) Lackluster Earnings

The market was pleased with the recent earnings report from AbbVie Inc. ( NYSE:ABBV ), despite the profit numbers being...
ナラティブの更新 • Apr 23

ABBV: Future Returns Will Rely On Immunology Expansion And Operating Leverage Execution

Analysts made a small upward adjustment to AbbVie’s fair value estimate to about $249. The modest change reflects a mix of slightly higher assumed discount rates and future P/E multiples, alongside recent shifts in Street price targets, including both raises and trims from firms such as Piper Sandler, Guggenheim, Cantor Fitzgerald, Evercore ISI, Citi and UBS, as well as fresh bullish initiations from Canaccord, RBC Capital and Barclays.
ナラティブの更新 • Apr 08

ABBV: Future Returns Will Hinge On Immunology Encore And Operating Leverage Execution

Analysts have made a modest upward adjustment to AbbVie’s price target, reflecting updated views on its immunology pipeline potential, operating leverage, and the ongoing debate about whether recent share underperformance and selloffs adequately reflect competitive risks. Analyst Commentary Recent research on AbbVie highlights a split view, with some analysts focusing on the upside from the immunology pipeline and operating leverage, while others point to valuation and competitive questions after a period of share underperformance.
ナラティブの更新 • Mar 24

ABBV: Future Returns Will Hinge On Immunology Encore Outweighing Competitive Concerns

Narrative Update The analyst price target for AbbVie has been adjusted slightly higher to reflect a fair value move to about $249. Analysts point to early stage indication expansion, operating leverage potential, and ongoing immunology pipeline developments, even as some firms flag emerging competition and a more balanced risk and reward profile.
ナラティブの更新 • Mar 10

ABBV: Future Returns Will Depend On Immunology Encore And Deal Optionality Uncertainty

The analyst price target for AbbVie edges higher to align with our fair value shift from $248.29 to $248.86, as analysts highlight ongoing indication expansion in immunology, potential operating leverage, and multiple expansion drivers, even as some firms note emerging competition and a more balanced risk and reward profile. Analyst Commentary Recent research on AbbVie reflects a split view, with some analysts pointing to upside tied to immunology growth and pipeline execution, while others flag competition risk and a more balanced risk and reward profile at current levels.
ナラティブの更新 • Feb 22

ABBV: Future Returns Will Rely On Immunology Encore And Evolving Deal Optionality

Our updated AbbVie narrative reflects a modest price target increase to about $248 per share, as analysts point to potential operating leverage, room for P/E multiple expansion, and a pipeline of proof-of-concept and immunology programs that could support slightly higher revenue growth assumptions, even as margin expectations are trimmed. Analyst Commentary Recent research shows a mix of optimism and caution around AbbVie, with several firms adjusting price targets and ratings as they reassess execution risks, competitive pressures, and the potential impact of the pipeline on valuation.
ナラティブの更新 • Feb 07

ABBV: Future Returns Will Depend On Immunology Pipeline Clarity And M&A Uncertainty

Analysts have trimmed their price targets for AbbVie by a small amount. This reflects slightly lower revenue growth and P/E assumptions, while also incorporating a modestly higher profit margin and recent mixed research views around competition and pipeline visibility.
ナラティブの更新 • Jan 24

ABBV: Future Returns Will Hinge On Post-Humira Immunology And Deal Optionality

Analysts have nudged their price target for AbbVie slightly higher to reflect a fair value estimate of about $245 per share, supported by updated assumptions for revenue growth, profit margins, and a modestly lower future P/E. Recent research highlights both increased price targets and more cautious views around competition and the sustainability of outperformance in key immunology drugs.
ナラティブの更新 • Jan 09

ABBV: Future Returns Will Depend On Post-Humira Immunology And Pipeline Execution

Analysts have trimmed their AbbVie fair value estimate by about $0.10 per share to roughly $244.56. This reflects a mix of slightly higher risk assumptions, modestly adjusted revenue and margin expectations, and a more balanced set of views after recent downgrades and price target changes that suggest outperformance is already well reflected in the current share price.
分析記事 • Jan 08

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

AbbVie Inc. ( NYSE:ABBV ) will increase its dividend from last year's comparable payment on the 17th of February to...
ナラティブの更新 • Dec 21

ABBV: Future Returns Will Hinge On Post-Humira Immunology And Pipeline Execution

Analysts have nudged our AbbVie fair value estimate slightly higher, from $243.55 to $244.68. This reflects modestly stronger long term revenue growth expectations for key immunology franchises and pipeline assets, partially offset by slightly lower margin assumptions and a broadly constructive but mixed backdrop of recent price target revisions and rating changes across the Street.
ナラティブの更新 • Dec 07

ABBV: Future Performance Will Depend On Extended Exclusivity And Pipeline Execution

Analysts have nudged their average price target on AbbVie modestly higher to reflect a wave of target increases into the mid 240s to low 260s dollar range, supported by stronger visibility into Skyrizi and Rinvoq driven growth, extended Rinvoq exclusivity, and a more favorable large cap biopharma backdrop despite mixed ratings changes. Analyst Commentary Recent research paints a generally constructive picture on AbbVie, with most price target revisions skewing higher even as some firms move to the sidelines.
分析記事 • Dec 02

AbbVie (NYSE:ABBV) Is Increasing Its Dividend To $1.73

The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...
ナラティブの更新 • Nov 23

ABBV: Future Performance Will Depend On Pipeline Expansion And Patent Protections

AbbVie’s analyst price target has increased modestly from $241.29 to $243.55. Analysts cite resilient performance in immunology products, extended Rinvoq exclusivity, and improving fundamentals as key drivers of sentiment.
分析記事 • Nov 18

AbbVie's (NYSE:ABBV) Dividend Will Be Increased To $1.73

The board of AbbVie Inc. ( NYSE:ABBV ) has announced that it will be paying its dividend of $1.73 on the 17th of...
ナラティブの更新 • Nov 08

ABBV: Future Performance Will Reflect Balance Between Patent Wins and Product Pressures

AbbVie's analyst price target has risen modestly from $237.48 to $241.29. Analysts cite resilient fundamentals and long-term patent settlements, which help offset recent industry downgrades and softer performance in some business units.
ナラティブの更新 • Oct 25

Continued Expansion in Neuroscience and Immunology Will Drive Leadership Beyond 2025

AbbVie's analyst price target has been raised from approximately $233 to $237 per share. Analysts cite ongoing revenue growth, improved margins, and extended exclusivity for key products as the main drivers behind the upward revision.
ナラティブの更新 • Oct 11

Expanding Immunology And Neuroscience Will Reshape Global Healthcare

AbbVie's analyst price target has increased significantly, rising from $227 to $233 per share. Analysts cite recent positive developments in patent settlements and stronger-than-expected performance across key growth drivers as the main rationales.

業績と収益の成長予測

NYSE:ABBV - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202878,09221,85534,42533,18719
12/31/202772,73219,02333,34730,28224
12/31/202667,23814,56129,40225,44724
3/31/202662,8193,59519,98021,224N/A
12/31/202561,1604,18617,81619,030N/A
9/30/202559,6442,34819,68420,860N/A
6/30/202558,3283,72318,23919,283N/A
3/31/202557,3674,15515,38516,401N/A
12/31/202456,3344,23817,83218,806N/A
9/30/202455,5335,08115,62316,511N/A
6/30/202455,0005,29817,78018,638N/A
3/31/202454,4035,95121,89122,686N/A
12/31/202354,3184,82022,06222,839N/A
9/30/202355,1386,47124,72925,514N/A
6/30/202356,0238,63524,79925,542N/A
3/31/202356,7417,53523,52024,228N/A
12/31/202258,05411,78224,24824,943N/A
9/30/202257,81913,34321,92122,590N/A
6/30/202257,34912,56922,21422,923N/A
3/31/202256,72512,40722,04722,808N/A
12/31/202156,19711,46821,99022,777N/A
9/30/202155,1697,46521,67722,556N/A
6/30/202153,7296,59919,57220,451N/A
3/31/202150,1955,09217,78918,650N/A
12/31/202045,8044,55616,79017,588N/A
9/30/202040,6507,32415,32716,009N/A
6/30/202036,2276,90614,11514,734N/A
3/31/202034,0578,39513,55214,122N/A
12/31/201933,2667,842N/A13,324N/A
9/30/201932,8673,232N/A13,441N/A
6/30/201932,6244,093N/A13,410N/A
3/31/201932,6475,333N/A13,799N/A
12/31/201832,7535,657N/A13,427N/A
9/30/201832,1877,531N/A12,619N/A
6/30/201830,9466,419N/A11,366N/A
3/31/201829,6126,352N/A10,503N/A
12/31/201728,2165,283N/A9,960N/A
9/30/201727,2736,615N/A8,917N/A
6/30/201726,7106,582N/A7,100N/A
3/31/201726,2186,278N/A7,015N/A
12/31/201625,6385,923N/A7,041N/A
9/30/201625,2426,048N/A7,463N/A
6/30/201624,7545,690N/A8,164N/A
3/31/201623,7775,448N/A8,078N/A
12/31/201522,8595,118N/A7,535N/A
9/30/201521,9112,790N/A4,994N/A

アナリストによる今後の成長予測

収入対貯蓄率: ABBVの予測収益成長率 (年間26.7% ) は 貯蓄率 ( 3.5% ) を上回っています。

収益対市場: ABBVの収益 ( 26.7% ) はUS市場 ( 18.4% ) よりも速いペースで成長すると予測されています。

高成長収益: ABBVの収益は今後 3 年間で 大幅に 増加すると予想されています。

収益対市場: ABBVの収益 ( 6.3% ) US市場 ( 12.7% ) よりも低い成長が予測されています。

高い収益成長: ABBVの収益 ( 6.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: ABBVの 自己資本利益率 は、3年後には非常に高くなると予測されています ( 228.1 %)。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/07/05 03:01
終値2026/07/02 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

AbbVie Inc. 24 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。51

アナリスト機関
David ToungArgus Research Company
Emily FieldBarclays
Luisa HectorBerenberg